Date: 2013-09-03
Type of information: Commercialisation agreement
Compound: ConfirmMDx™ for prostate cancer test
Company: MDX Health (Belgium) - Stratose (USA)
Therapeutic area: Cancer - Oncology
Type agreement: commercialisation
Action mechanism: ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or \"halo\" associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular \"halo\" around a cancer lesion can be present despite having a normal appearance under the microscope.
Disease: prostate cancer
Details: * On September 3, 2013, MDxHealth, a belgian molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, has announced that it has entered into an agreement with Stratose, one of the largest healthcare PPO network providers in the U.S. The agreement provides Stratose\'s 12.4 million member network with access to ConfirmMDx™ for Prostate Cancer testing. Stratose (formerly operating as Coalition America, NPPN, OPPN, PlanCare America, 4MOST Health, Qualident and KeyClaims) maintains one of the largest directly managed PPO networks in the U.S., including more than 850,000 direct and affiliate medical, dental and workers\' compensation provider contracts.
Financial terms:
Latest news:
